June 24th, 2011 08:42am
NOVATO, CA — Preclinical research on the possibility of treating Parkinson’s disease with lithium is under way at the Buck Institute for Age Research, which is working toward beginning a second phase of clinical studies on humans treated with the drug in conjunction with standard therapy.
Lithium “profoundly” prevents the cell loss and aggregation of toxic proteins associated with Parkinson’s in a mouse model of the condition, according to the Buck. The new research appears in today’s online edition of the Journal of Neuroscience Research.
[Read full article]
No comments:
Post a Comment
Please be constructive in your comments.